FILTER BY:
Details
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Address: 1901 East Rd, Houston, TX 77054, USA
Phone: 877-451-7009
Mesothelioma Type:
- Pleural: True
- Peritoneal: True
- Pericardial: True
- Tunica Vaginalis: True
Type: Epitheliod, Biphasic, Sarcomatoid
Condition: CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Description: This phase II trial studies how well brentuximab vedotin works in treating patients with CD30 positive (+) malignant mesothelioma that cannot be removed by surgery. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of tumor cells to grow and spread.
Research Center: MD Anderson Cancer Center
Treatment Interventions: DRUG: Brentuximab Vedotin, OTHER: Laboratory Biomarker Analysis
Potential Impact: Low
Clinical Trial Number: NCT03007030
Phase: Phase 2
Status: Recruiting
